BioSpace News Archive

Rocket Pharmaceuticals, Inc. today announces an oral presentation of previously disclosed data from the ongoing Phase 1 trial of RP-A501 for the treatment of Danon Disease was given at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2021.

Dante Labs today announced the appointments of Andre Nel, Dalila Rahmani, Laura D’Angelo and Omar Elbakshish to the company’s management team, expanding its global leadership to help scale the growing business.

Phase I/II investigator-Initiated Trial to be conducted at Weill Cornell Medicine, led by Principal Investigator, Dr. Scott T. Tagawa

Immunophotonics, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary immune-activating carbohydrate polymers for the treatment of metastatic cancers, has announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 11111316.

inTRAvent’s Bedside Neuro-Navigation Device Receives FDA 510(k) Clearance

Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that its lead candidate, MSP-1014, was comparable to psilocybin assessed using a drug discrimination assay.

Titan Medical Inc. today announced that David McNally, President and CEO of Titan Medical, will present an overview of the company and its Enos™ robotic single access surgical system and participate in one-on-one investor meetings at two upcoming investor conferences.

Cepheid today announced it has received Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration (FDA) for Xpert Xpress CoV-2/Flu/RSV plus

Nuvectis Pharma, Inc., a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, announced today that it has licensed exclusive worldwide rights to develop and commercialize a novel, oral, small molecule, SRC/YES1 inhibitor from the University of Edinburgh in Scotland.

Progenity, Inc. announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,112,403 for assessment of preeclampsia using assays for free and dissociated placental growth factor.